Abcellera Biologics (ABCL) revenue and earnings history
Abcellera Biologics reported revenue of $75.1M for fiscal 2025 (year ended Dec 31, 2025), +160.6% on the year before, and net income of −$146M.
Over 6 years, from fiscal 2019 to fiscal 2025, revenue grew at a compound rate of +36.5% a year.
Revenue and net income, 7 fiscal years
Annual figures, newest first
| Fiscal year | Revenue | Operating income | Net income | Operating cash flow | Capital expenditure | Free cash flow | Stock-based pay | Share buybacks | Dividends paid | Cash at year end | Total debt at year end | Report |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025ended Dec 31, 2025 | $75.1M+160.6% | −$217M | −$146M | −$131M | $42.8M | −$174M | $55.8M | — | — | $129M | — | 10-K |
| 2024ended Dec 31, 2024 |
The latest quarter, insider trades and fund moves: Abcellera Biologics (ABCL) on OQRO.
Common questions
What was Abcellera Biologics's revenue in fiscal 2025?
$75.1M for the year ended Dec 31, 2025, as reported in its 10-K filed Feb 24, 2026. That is +160.6% on fiscal 2024 ($28.8M).
How fast has Abcellera Biologics's revenue grown?
From $11.6M in fiscal 2019 to $75.1M in fiscal 2025: a compound annual growth rate of +36.5% over 6 years. This is arithmetic on the filed figures and says nothing about the years ahead.
Has Abcellera Biologics been profitable?
Where these figures come from
The SEC’s companyfacts data: every figure Abcellera Biologics tagged in XBRL in its annual and quarterly reports since 2009 (some reports carry a few earlier years as comparatives). For each fiscal year OQRO keeps the twelve-month totals from the annual report and the cash and debt at year end, and when a later report restates a year, the later figure. Read again whenever the company files.
Figures are as reported, in US dollars, with no adjustment for acquisitions, disposals or one-off items. Earnings per share are left out because a stock split changes them between reports. This page describes the past and is not investment advice. No language model wrote it.
